• International Summer School: Emerging Targets and Combination Therapies - Hybrid (In-class + Digital Event)

    The "Summer School of Immuno-Oncology: Emerging targets and combination therapies" aims to discuss knowledge and recent advances in the field of cancer immunotherapy. A panel of national and international lecturers will cover various aspects of preclinical and clinical immuno-oncology, ranging from the study of basic pathogenetic mechanisms for the discovery of new immunotherapeutic targets to more clinical aspects related to the effectiveness of combinatorial approaches in boosting cancer immunotherapy. The school will provide young oncologists, PhDs and PhD students, involved in clinical and research projects related to cancer immunotherapy, with a solid background in novel immuno-oncology topics. In particular, we will focus on issues related to: inflammation and cancer; the immunity-cancer interface: mutational load of the tumor and editing of immune responses; myelopoietic alterations, tumor microenvironment and anticancer immunotherapy; radioimmunotherapy and immunotherapy of blood cancers; clinical immunotherapy; antiviral response of the host and cancer development; role of immunosenescence and inflammaging in neoplasms; and immunological disorders and cancer. Furthermore, advanced knowledge on statistics will be provided for the analysis of preclinical and clinical data. The goal is to discuss the current state of knowledge in the field of cancer immunotherapy from an interdisciplinary and translational “bench-to-bedside” standpoint.

    The official language of the course is English. No simultaneous translation will be provided.

  • Modalità di partecipazione

    Per garantire il rispetto delle disposizioni sanitarie in materia di Covid 19, questo evento si svolgerà in forma ibrida. Sarà possibile seguire l’attività formativa in presenza presso la sede congressuale (Corso Residenziale) o in remoto (Evento Digitale).

    I due pulsanti sottostanti permettono di iscriversi secondo la modalità desiderata, fino ad esaurimento dei posti disponibili. L’iscrizione all’attività potrà avvenire esclusivamente attraverso procedura online, non saranno accettati nuovi iscritti presso la sede congressuale.

    Posti terminati per il Corso Residenziale. 
    Iscrizioni ancora aperte per l'Evento Digitale.

    Vai al Corso Residenziale

    Vai all'Evento Digitale

    AccMed si riserva di realizzare l’evento esclusivamente in modalità digitale qualora la situazione dell’emergenza sanitaria da Covid-19 lo rendesse necessario. In tal caso, sarà cura di AccMed informare docenti e iscritti della variazione nella modalità di fruizione dell’evento.

    I partecipanti che seguiranno l'attività in remoto avranno bisogno di una connessione internet di buona qualità e di un dispositivo (PC, Smartphone, Tablet) con browser Internet recente (es. qualsiasi versione aggiornata di Chrome o Firefox).

    Prenotazioni alberghiere:
    Telefono: 010.83794243
    E-mail: booking@forumservice.net

  • Programma dell’attività formativa

    Monday, 30th August

    10.00 - Registration and welcome coffee

    10.30 - Opening Address (Gian Carlo Avanzi, Marco Krengli)

    11.00 - Introduction to the school and programme presentation (Marisa Gariglio, Alessandra Gennari, Antonio Sica)

    11.30 - Opening Lecture: Cancer and Inflammation (Alberto Mantovani)            Chairmen: Gian Carlo Avanzi, Antonio Sica

    12.30 - Lunch break

    AFTERNOON SESSION: The cancer-immune system interface
    Chairmen: Gianluca Aimaretti, Ciro Isidoro

    14.00 - Tumor mutational load and cancer therapy (Giovanni Germano)

    14.45    Targeting adaptive immunity in cancer (Enrico Lugli)

     15.30 - Coffee break

    16.00 - Professional antigen presenting cells/DC in cancer (Silvano Sozzani)

    16.45 - Immune checkpoints in cancer therapy (Andrea Anichini)

    17.30 - Discussion
    Facilitator: Antonio Sica

    18.00 - Adjourn

    Tuesday, 31st August
                 

    MORNING SESSION: Anticancer immunotherapies: pros and cons
    Chairmen: Umberto Dianzani, Antonia Follenzi

    8.40 - Lecture: Update on anticancer immunotherapies
    Paolo Antonio Ascierto

    9.40 - Extracellular Matrix at the cross-road between cancer and immunity (Mario Colombo) 

    10.00 - Tumor microenvironment and emergency hematopoiesis (Laura Strauss)

    10.30 - Coffee Break

    11.00 - Suppressor myeloid cells in cancer (Vincenzo Bronte( 

    11.30 NK in cancer therapy (Angela Santoni)

    12.00 - Discussione Q&A
    Facilitator: Gianluca Gaidano

    12.30 - Giovanni Melillo interviewed by Pier Luigi Canonico (NO CME)

    13.00 - Lunch Break

    AFTERNOON SESSION: Hemato & Radio Immunotherapy
    Chairmen: Marco Krengli, Andrea Riccardo Filippi

    14.30 - Radiotherapy and immunotherapy: current knowledge of a clinical partnership (Pierfrancesco Franco)

    15.00 - Radiotherapy effects on tumor micro-environment (Andrea Riccardo Filippi)

    15.30 - SBRT and immunotherapy, a winning partnership? (Davide Franceschini) 

    15.50 - Coffee Break

    AFTERNOON SESSION: Hemato & Radio Immunotherapy
    Chairmen: Gianluca Gaidano, Giovanni Martinelli

    16.20 - Molecular determinants of immune-response (Massimo Dominici)

    16.40 - Immune checkpoints inhibitors in liquid tumors (Gianluca Gaidano)           

    17.10 - CAR-T cells (Marco Ladetto)

    17.30 - Discussion Q&A 
    Facilitator: Giovanni Martinelli

    18.15 - CME Session Adjourn

    18.30 - Cocktail with the statisticians – (NO CME)
    Chairmen: Paolo Bruzzi, Fabrizio Faggiano, Giovanni Melillo

    Methodological challenges in Phase I Immuno Clinical Trials (Giovanni Melillo) (15 min)

    Innovative trial design – Adaptive Immunotherapy Trials Oriana Nanni, Valter Torri (15 min)

    Endpoints & Summary Indicators in Immunotherapy Trials Paolo Bruzzi (15 min)

    Wednesday, 1st September
                 

    MORNING SESSION: Immunotherapy in the Clinic
    Chairmen: Pier Luigi Canonico, Alessandra Gennari

    9.00 - Lecture: Regulatory Process and clinical benefit (Armando Genazzani)

    9.40 - IO & Lung Cancer (Silvia Novello)           

    10.00 - IO & Urology (Matteo Bellone)

    10.20 - Immunotherapy of Melanoma: what we already know and future perspectives (Michele Del Vecchio)

    10.40 Coffee Break

    11.00 - Breast Cancer: evolution of innovative agents from CDK 4/6 to checkpoint inhibitors (Valentina Guarneri) 

    11.20 - IO & Hepatocellular carcinoma (David J. Pinato)

    11.40 - Innovative IO therapies in solid tumors: CAR-T, oncolytic viruses and beyond (Giuseppe Curigliano)

    12.15 - Antiandrogenic therapy in prostate cancer and COVID (Andrea Alimonti)

    12.30 - Discussion Q&A
    Facilitator: Alessandra Gennari

    13.00 - Lunch Break

    AFTERNOON SESSION: The complex interplay between SARS-CoV-2 and the host immune response
    Chairmen: Marisa Gariglio, Santo Landolfo

    14.30 - Vaccines and monoclonals to regain our freedom (Rino Rappuoli)

    15.10 SARS COV2 variants (Nicole Fischer) 

    15.50 - Innate RNA sensing of SARS-CoV2 and strategies of viral evasion (John Hiscott)

    16.30 Coffee Break

    17.00 - The cGAS-STING pathway in COVID-19 – protective and pathogenic potential (Soren Paludan) 

    17.40 - Discussion Q&A
    Facilitator: Marco De Andrea

    18.00 - Adjourn

    Thursday, 2nd September
            

    MORNING SESSION: Immunosenescence, Inflammaging and Cancer
    Chairmen: Lia Rimondini, Annalisa Chiocchetti

    9.00 - Inflammaging and Cancer (Massimiliano Bonafè)

    9.50 - Common mechanisms of age-related diseases: implication for disease-specific biomarkers identification (Fabiola Olivieri) 

    10.40 - Coffee Break

    11.10 - Genetics and Epigenetics of Aging (Paolo Garagnani)

    12.00 - Discussion Q&A
    Facilitator: Ciro Isidoro

    12.30 - Lunch Break

    AFTERNOON SESSION: Immunological disorders and cancer prognosis and therapy
    Chairmen: Claudio Santoro, Mario Pirisi

    14.00 - Allergy/autoimmunity and cancer (Marinos Kallikourdis)

    14.50 - Microbioma, immunity and cancer (Maria Rescigno) 

    15.10 - Tertiary lymphoid structures in immunology and immunotherapy (Catherine Fridman) 

    15.30 - Discussion Q&A
    Facilitator: Antonio Sica

    16.00 - Closing Lecture: B cells and antibodies, the next challenge in immunotherapy (Wolf Fridman)  

    16.30 - Adjournment and final evaluation questionnaire (Marisa Gariglio, Alessandra Gennari, Antonio Sica)